Autologous Peripheral Blood Mononuclear Cell Recognition of Autologous Proliferating Tumor Cells in the Context of a Patient-Specific Vaccine Trial
Figure 3
The induction of IFN-γ secreting lymphocytes in response to autologous tumor cells and correlation to either progression-free or overall survival at either week 0 or week 4. Patient cohorts were grouped according to whether they had an average of greater than (>) or less than (<) 5 spots/100 K PBMC per well observed at week 0 and week 4. Sample sizes: Week 0, for >5 spots/well and 22 for <5 spots/well, and for week 4, for >5 spots/well and 22 for <5 spots/well. Log-rank testing was used to determine values.
